最新ニュース Procaps Gr (NASDAQ:PROC) 株価情報

Procaps Gr

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Procaps Group SA

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

PROCREDIT HOLDING AG by Procredit Holding Ag

ProCredit Holding AG

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Procore Technologies Inc

Procter & Gamble Company (The) Common Stock

Procter & Gamble Co

Procure ETF Trust II Disaster Recovery Strategy ETF

Procure Space ETF

Procurri Corp Ltd

Procyon Corp

As of today, the U.S. debt has skyrocketed to $36 trillion and around one in every five dollars the government spends goes straight into repaying investors. In addition to causing the government a great deal of trouble, this scenario is also becoming a potential stumbling block for Donald Trump&#8217;s economic ambitions and <a href="https://www.benzinga.com/24/11/42131911/donald-trump-appointed-doge-to-have-marginal-impact-saving-50-100-billion-says-analyst-as-elon-musk-aims-to-target-500-billion-plus-in-federal-expenditures">will impact</a> the new government agency headed by Musk and Ramaswamy.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
The U.S. federal debt is growing relentlessly. According to White House debt <a href="https://www.whitehouse.gov/wp-content/uploads/2023/03/hist07z1_fy2024.xlsx">data</a>, it was $19.5 trillion in 2016, shortly before Trump was elected. It <a href="https://www.benzinga.com/personal-finance/24/10/41564246/from-10-trillion-to-35-trillion-how-government-spending-has-spiraled-out-of-control">skyrocketed</a> to $26.9 trillion by 2020 and now is nearly <a href="https://www.crfb.org/press-releases/gross-national-debt-reaches-36-trillion">$36 trillion</a>. "The point is that fiscal policy reflects joint action by Congress and the president," David Primo, a University of Rochester professor of political science and business administration, told AP. This directly impacts how the government functions, so it&#8217;s not just about numbers.
According to the <a href="https://www.fiscal.treasury.gov/files/reports-statements/mts/mts0824.pdf">Congressional Budget Office</a> (CBO), interest payments alone will total more than $1 trillion in the upcoming year. The government intends to spend less on national security than on these payments. What&#8217;s worse, rising debt service costs are crowding out essential programs like infrastructure, education and health care – areas that are supposed to contribute to future growth.
See Also: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
<h2 class="wp-block-heading">Big Promises, Bigger Obstacles</h2>
Trump has talked about big economic plans, including <a href="https://www.benzinga.com/government/regulations/24/11/41885777/how-trumps-tax-cuts-tariffs-animal-spirits-could-shape-sp-500-earnings">tax cuts and tariffs</a>. But the rising cost of paying off existing debt means there's less room for these moves. The costs of servicing this huge debt leave Trump with fewer options for ambitious economic measures. Increased debt restricts the federal budget&#8217;s flexibility, making it more difficult to enact tax cuts that Trump claims would help the middle class.
Critics argue that Trump&#8217;s proposed tax cuts, like those from 2017, largely benefit the wealthiest Americans and <a href="https://www.benzinga.com/government/24/06/39462030/trump-added-nearly-two-times-more-to-the-national-debt-than-biden-while-in-office-new-report">add to the already ballooning debt</a>. Additionally, rising national debt tends to raise interest rates, making it more expensive for Americans to purchase houses, vehicles or make long-term investments.&nbsp;
Trending: Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">The Forces Pulling Interest Rates</h2>
Jeffrey Schmid, the president of the Kansas City Fed, has recently stressed that <a href="https://www.benzinga.com/24/11/42075235/feds-schmid-rising-us-national-debt-could-push-interest-rates-higher">three significant factors</a> influence interest rates: growing debt, an aging population and productivity growth. Productivity gains, especially driven by new tech like AI, could mean higher rates. However, an aging population and the tendency of older generations to save more could push rates lower. &#8220;While now is the time to begin dialing back the restrictiveness of monetary policy, it remains to be seen how much further interest rates will decline or where they might eventually settle,&#8221; Schmid said.
With a $36 trillion bill, the government must keep attracting investors to buy its bonds, which will mean offering higher interest rates.
Without major adjustments, the national debt will continue destabilizing the economy, making it even harder for investors and the government to take risks. The effectiveness of this new agency&#8217;s cost-cutting initiatives will change in conjunction with interest rate fluctuations. The ongoing question is whether productivity and new technology can save the day or if the growing debt will push rates further, limiting economic growth and complicating the agency&#8217;s mission to streamline spending.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

1 In 5 Dollars The Government Expends Goes To Repaying Investors. Here's Why This Spells Trouble For Trump And DOGE

France maintains one of the strictest cannabis policies in Europe, prohibiting recreational use, possession and cultivation. Paradoxically, it also has the highest <a href="http://benzinga.com/cannabis">cannabis</a> consumption rate on the continent. As the French government grapples with mounting public debt –currently at 112% of GDP– legalizing and taxing cannabis presents a potential fiscal lifeline.  
<h3 class="wp-block-heading">France Could Unlock Major Gains By Legalizing</h3>
The country&#8217;s stringent laws lead to significant law enforcement costs and strain on the judicial system. <a href="https://www.theguardian.com/commentisfree/2024/nov/27/france-cannabis-consumption-europe-tax-decriminalisation-crime">According</a> to The Guardian, approximately 200,000 people pass through the criminal justice system annually on drug-related charges, with substantial resources allocated to anti-cannabis efforts.
However, economic analysts consulted by The Guardian suggest that legalizing cannabis could alleviate France&#8217;s financial challenges. A 2019 <a href="https://shs.cairn.info/revue-notes-du-conseil-d-analyse-economique-2019-4-page-1?lang=fr#s1n7">study</a> by an economic advisory board within the Prime Minister&#8217;s office estimated that legalization could generate €2.8 billion ($2.9 billion) in fiscal receipts and create up to 80,000 jobs.
<h3 class="wp-block-heading">High Anti-Cannabis Costs Amid Economic Strain</h3>
Legalization proponents argue it could also reduce gang-related crime by removing a lucrative market from criminal networks. Moreover, regulated sales might undercut illegal dealers and decrease street violence associated with drug trafficking.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
These revenues, combined with savings on enforcement costs, could also provide much-needed relief as the government contemplates unpopular tax hikes and spending cuts. With national debt at €3.2 trillion and a budget deficit projected at 6% for 2024, cannabis could offer France a much-needed financial boost.
<h3 class="wp-block-heading">Future of French Medical Cannabis In Limbo</h3>
Meanwhile, despite the potential benefits of legalizing, France&#8217;s medical marijuana trial <a href="https://www.benzinga.com/markets/cannabis/24/10/41503963/frances-medical-marijuana-trial-faces-uncertainty-as-new-amendment-tries-to-keep-it-running">faces delays and political uncertainty</a>. Originally set to end in March 2024, the program now hinges on a proposed amendment to extend it through 2025. Political delays have prevented alignment with European regulations, leaving the future of medical cannabis in limbo.&nbsp;
Without immediate action, over 2,000 patients could lose access to treatments, highlighting the need for a permanent framework.&nbsp;&nbsp;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38029760/cannabis-on-the-rise-in-europe-why-germanys-legalization-is-a-game-changer-for-the-ecosystem">Cannabis On The Rise In Europe: Why Germany&#8217;s Legalization Is A Game Changer For The Ecosystem</a>
<h3 class="wp-block-heading">Neighbors Diverge: Germany Lights Up</h3>
In contrast, Germany's cannabis market exemplifies a more progressive approach. Its Cannabis Control Act, enacted earlier this year, has spurred rapid growth. Sanity Group, a leading German cannabis company, <a href="https://www.benzinga.com/markets/cannabis/24/10/41336543/is-germany-set-to-become-next-cannabis-giant-we-tripled-within-one-year-says-industry-insider">reported tripling its revenue within a year</a> due to regulatory changes. Germany's potential expansion into adult-use cannabis could further establish it as Europe's cannabis leader.&nbsp;&nbsp;
With <a href="https://www.benzinga.com/markets/cannabis/24/11/42043465/czech-government-legalizes-cultivation-of-three-cannabis-plants-allows-possession-of-50-grams">evidence from neighboring countries</a> and <a href="https://www.benzinga.com/markets/cannabis/22/04/26520421/majority-of-europeans-support-cannabis-legalization-which-country-will-do-something-about-it">growing public discourse</a>, France faces increasing pressure to reconsider its strict policies. Legalization could not only address fiscal challenges but also position France as a competitor in the burgeoning European cannabis industry.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42162875/canopy-growths-german-subsidiary-teams-up-with-portugals-gro-vida-to-expand-medical-cannabis-supply">Canopy Growth&#8217;s German Subsidiary Teams Up With Portugal&#8217;s Gro-Vida To Expand Medical Cannabis Supply</a></li>
</ul>
Image generated with AI tools.

Cannabis

Eurozone

Europe's Top Cannabis Consumer Still Criminalizes Use, Forfeits Economic Gains

Planning to <a href="https://www.benzinga.com/personal-finance/24/09/40964924/most-people-expect-to-retire-at-67-but-56-retire-sooner-can-you-guess-the-actual-average-retirem">retire at a specific age</a> often involves careful preparation, but reality doesn't always align with expectations. A new study by the Employee Benefit Research Institute (EBRI) found that 58% of retirees leave the workforce earlier than planned, frequently due to factors beyond their control.
EBRI's 2024 Spending In Retirement study, which surveyed 3,600 retirees aged 62 to 75, reveals some of the reasons for early retirement and the financial challenges that come from it.&nbsp;
Don't Miss:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
<h2 class="wp-block-heading">Why Do People Retire Early?</h2>
For some, <a href="https://www.benzinga.com/personal-finance/24/10/41185972/is-65-too-early-to-retire-new-research-says-it-might-be-45-of-households-are-expected-to-run-out">retiring early</a> is a strategic choice. They've built their nest egg and have methodically planned for early retirement. For others, it isn't always within their control.&nbsp;
Health issues and workplace reorganization are the leading factors behind why many Americans retire early. According to the EBRI survey:&nbsp;
<ul>
<li>38% of those who retired earlier than expected cited health problems or disabilities as the main reason. </li>
<li>23% stated that company-related issues like downsizing, closures or reorganizations were the cause. </li>
</ul>
Roughly two out of five of those who retired early did so because they felt financially prepared. However, this group represents a minority compared to those whose circumstances necessitated an earlier exit.&nbsp;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">Financial Struggles Among Early Retirees</h2>
Leaving the workforce sooner than expected can have negative financial implications. Early retirees have less time to <a href="https://www.benzinga.com/personal-finance/24/11/41918104/are-you-on-track-to-retire-rich-heres-the-nest-egg-you-need-to-be-considered-a-wealthy-retiree">save for retirement</a>, requiring them to stretch their existing savings across a longer period of time.&nbsp;
A similar study by John Hancock Financial found that early retirees are more likely to face financial stress for several reasons:&nbsp;
<ul>
<li>33% of those who retire early rely solely on Social Security for their income, compared to just 11% of those who retired when they planned.</li>
<li>Over half reported cutting back on spending and 45% downsized their living arrangements to reduce costs.</li>
<li>With longer life expectancy, Americans must plan for funding a retirement that could span multiple decades, extending longer if they retire early. </li>
</ul>
The EBRI study also revealed that many retirees are unprepared for the financial demands of retirement. Half of retirees said they did not save as much as they needed and only one-third thought they had enough.&nbsp;
Trending: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
<h2 class="wp-block-heading">A Broader Retirement Reality</h2>
Despite the financial challenges, many retirees remain optimistic. Two-thirds of respondents in the EBRI study said they are living the retirement lifestyle they envisioned, even if getting there was difficult.
However, the findings from this study highlight an important lesson: while planning for the age you want to retire at is important, unforeseen circumstances can disrupt even the best-laid plans. Health issues, workplace changes and <a href="https://www.benzinga.com/personal-finance/24/09/40800774/gen-xs-looming-retirement-crisis-is-worse-than-they-realize-expert-compares-it-to-being-handed-a">insufficient savings</a> are all risks that retirees should prepare for to ensure a more secure financial future.
For those still working, start planning early and revisit your savings goals frequently to help mitigate challenges that may come if you must unexpectedly retire.&nbsp;
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

EBRI Study Reveals 58% Of Retirees Retire Earlier Than Expected, Here's Why

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 68.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 25.00% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 16.78% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 8.70% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 8.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 6.48% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 4.24% at $0.67</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.33% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.31% at $1.94</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 3.07% at $1.76</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MPXOF">MPX International</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPXOF#OTC">MPXOF</a>) shares closed down 33.33% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 32.15% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 31.19% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 30.82% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 14.71% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 10.60% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 9.20% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 6.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 5.80% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.96% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 3.90% at $0.08</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Movers

BBRRF

BMMJ

CLSH

CNBX

CNPOF

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

EAST

GBHPF

KAYS

LMLLF

LVRLF

MGWFF

MPXOF

NWVCF

RMHB

RSSFF

TGIFF

XXII

YCBD

Cannabis Stock Movers For November 28, 2024

Berkshire Hathaway Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) stock soared to unprecedented levels, closing Wednesday at $483.08 after touching a 52-week high of $491.67. 
<h2 class="wp-block-heading">Berkshire's Stock Surges to New Heights</h2>
The stock has been on a tear, boasting a 34% gain over the past year and 19.6% in the last six months. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28132715/Screenshot-2024-11-28-at-11.57.02-PM.png" alt="" class="wp-image-669243" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28132715/Screenshot-2024-11-28-at-11.57.02-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28132715/Screenshot-2024-11-28-at-11.57.02-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
With its price trading well above key moving averages—including a 200-day SMA of $430.63—technical indicators suggest the bullish trend is intact.
However, with the Relative Strength Index (RSI) at 68.79, the stock is teetering near overbought territory, raising questions about sustainability. Despite this, a Moving Average Convergence Divergence (MACD) reading of 5.56 signals continued strength.
Read Also: <a href="https://www.benzinga.com/personal-finance/24/11/42191171/warren-buffett-claims-he-killed-the-dow-investing-peanuts-and-explains-its-a-huge-structural-advantage-to-not-have-a-lot-of-money">Warren Buffett Claims He &#8216;Killed The Dow&#8217; Investing &#8216;Peanuts&#8217; – And Explains It&#8217;s A &#8216;Huge Structural Advantage To Not Have A Lot Of Money&#8217;</a>
<h2 class="wp-block-heading">Buffett's Generosity Knows No Bounds</h2>
Even as his net worth hits $150 billion, <a href="https://www.benzinga.com/topic/warren-buffett">Warren Buffett</a> isn't slowing down his philanthropic mission. On Monday, the Oracle of Omaha pledged another $1.15 billion worth of Berkshire stock to his family's charitable foundations, continuing his 2006 commitment to give away most of his wealth.
Buffett has now donated 56.6% of his Berkshire shares, solidifying his legacy as both an investing icon and a philanthropic force. His latest move follows a colorful shareholder<a href="https://www.businesswire.com/news/home/20241125323423/en/Berkshire-Hathaway-Inc.-News-Release"> letter</a>, where he reaffirmed his dedication to wealth redistribution.
<h2 class="wp-block-heading">A Wealth Legacy Like No Other</h2>
Buffett, who <a href="https://www.forbes.com/sites/dereksaul/2024/11/25/never-wished-to-create-a-dynasty-warren-buffett-donates-11-billion-in-berkshire-stock-and-updates-will/">ranks</a> as the sixth-richest person in the world, has more than doubled his fortune since 2014. Yet, he trails Elon Musk's $330 billion net worth by a significant margin. Unlike Musk's splashy ventures, Buffett's wealth engine—Berkshire Hathaway—continues its steady climb, reinforcing its position as a titan of diversified investing.
Investors are left wondering: can Berkshire maintain its momentum, or is the stock's RSI warning of a potential pullback? Either way, one thing remains clear: Buffett's empire isn't just breaking records—it's making history.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42143260/warren-buffett-claims-to-not-time-the-market-but-his-cash-horde-tells-a-different-story">Warren Buffett Claims To Not &#8216;Time The Market,&#8217; But His Cash Horde Tells A Different Story</a></li>
</ul>

Long Ideas

Technicals

Trading Ideas

Warren Buffett's Billion-Dollar Moves Propel Berkshire Stock To Record Highs

The commercial aerospace sector is gaining altitude, driven by surging demand for passenger travel, robust freight activity, and a <a href="https://www.benzinga.com/topic/expert-ideas">resurgence in aircraft orders</a>.
According to Goldman Sachs analyst Noah Poponak, CFA, air traffic recovery is exceeding expectations, with growth now outpacing GDP by more than double. 
The sector&#8217;s strong fundamentals, buoyed by tight supply chains and rising aftermarket revenues, are positioning key aerospace stocks for a significant takeoff.
Here&#8217;s what you need to know — and the top stocks analysts say you should have on your radar.
<h3 class="wp-block-heading">Air Traffic Surpasses Pre-Pandemic Levels</h3>
&#8220;The overall commercial aerospace market is fundamentally strong,&#8221; said Poponak in a note Thursday. 
Global passenger traffic continues its remarkable climb as international air traffic jumped 9% year-over-year (yoy) in September, following an 11% yoy increase in August, according to the International Air Transport Association (IATA). Passenger capacity rose in lockstep, up 9% and 10% yoy, respectively.
Goldman Sachs forecasts another 9% yoy gain for October based on airline reports. 
Forward airline schedules indicate that global passenger capacity will grow by 6% to 7% year-over-year through November, December, and January, reflecting sustained demand as travel appetite remains strong.
<h3 class="wp-block-heading">Freight Market Delivers Double-Digit Growth</h3>
The recovery isn't limited to passengers. International freight traffic surged 11% yoy in September, following a 12% yoy gain in August, with freight capacity expanding by 8% yoy in both months. 
Major cargo players FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) and United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) also saw gains, with UPS reporting 11% yoy growth and FedEx posting a 3% yoy increase in global air cargo traffic.
<h3 class="wp-block-heading">Boeing, Airbus Rack Up Orders</h3>
Large commercial jet manufacturers are riding the wave of demand. In October alone, Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) secured 63 new orders, while Airbus SE (OTCPK: EADSY) booked 82 aircraft orders—both with zero cancellations. 
&#8220;New aircraft order campaigning activity appears to remain robust, for both growth and replacement,&#8221; Poponak wrote. 
Parked aircraft, which currently make up 11.8% of the total global fleet, remained flat month-over-month, further reflecting high utilization levels as airlines capitalize on the recovery in passenger and freight traffic.
<h3 class="wp-block-heading">Goldman Sachs' Top Stock Picks</h3>
Goldman Sachs&#8217; Poponak highlighted 11 buy-rated stocks that stand to benefit from the industry's resurgence. These include large aircraft manufacturers, component suppliers, and business jet producers.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>)</td>
<td>Aerospace Systems</td>
</tr>
<tr>
<td>Boeing Co.</td>
<td>Large Aircraft</td>
</tr>
<tr>
<td>TransDigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>)</td>
<td>Aircraft Components</td>
</tr>
<tr>
<td>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)</td>
<td>Engine Manufacturing</td>
</tr>
<tr>
<td>HEICO Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>)</td>
<td>Aircraft Parts</td>
</tr>
<tr>
<td>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>)</td>
<td>Aerospace Materials</td>
</tr>
<tr>
<td>Ducommun Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>)</td>
<td>Aerospace Electronics</td>
</tr>
<tr>
<td>CAE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>)</td>
<td>Simulation &amp; Training</td>
</tr>
<tr>
<td>Bombardier Inc. (OTCPK: BOMBF)</td>
<td>Business Jets</td>
</tr>
<tr>
<td>Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>)</td>
<td>Regional Aircraft</td>
</tr>
<tr>
<td>Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) </td>
<td>Business Jets &amp; Helicopters</td>
</tr>
</tbody>
</table>
</figure>
Among these, Woodward (WWD) is singled out for its placement on Goldman's &#8220;Conviction List,&#8221; while Boeing remains a flagship name for its leadership in large commercial jets.

Analyst Color

Equities

Large Cap

Mid Cap

BOMBF

European Aeronautic Defence And Space Unsponsored

EADSY

Embraer-Empresa Brasileira De Aeronautica

Aerospace Ready To Take Off: Goldman Sachs Reveals 11 Top Picks In The Sector

In the current session, the stock is trading at $139.73, after a 0.62% spike. Over the past month, Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) stock increased by 19.28%, and in the past year, by 65.85%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732824015_0.png" alt="Past Year Chart" />

<h3>Comparing Live Nation Entertainment P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Live Nation Entertainment has a better P/E ratio of 156.03 than the aggregate P/E ratio of 41.7 of the Entertainment industry. Ideally, one might believe that Live Nation Entertainment Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732824016_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

P/E Ratio Insights for Live Nation Entertainment

For income-focused investors, <a href="https://www.benzinga.com/real-estate/reit">real estate investment trusts (REITs)</a> are a goldmine, offering steady dividends backed by tangible assets. 
Our search for top REITs focused on large-cap stocks from the S&amp;P 500 index with a dividend yield exceeding 5% and Wall Street analysts rating them a "Buy" or higher. This rigorous filter led us to three standout picks that combine high yield with growth potential. From healthcare facilities to retail and casinos, these REITs provide both robust income and diversified exposure.
<h2 class="wp-block-heading">1. Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): A Prescription For Income</h2>
Dividend Yield: 5.40% Market Cap: $15.81 billion Sector: Healthcare Facilities
Healthpeak Properties is a healthcare-focused REIT with a flair for stability and growth. Offering a 5.40% dividend yield, DOC has seen a stellar 30.67% performance over the past year and 12.32% year-to-date gains. Its price-to-free-cash-flow (P/FCF) ratio of 18.41 signals a fair valuation, making it an attractive choice for yield-seeking investors.
With the healthcare sector&#8217;s resilience, Healthpeak benefits from long-term demographic trends like aging populations, positioning itself as a dependable dividend payer in a defensive industry.
Read Also: <a href="https://www.benzinga.com/real-estate/reit/24/11/42068836/crowdstreets-new-ceo-john-imbriglia-charts-a-bold-path-for-commercial-real-estate-investors">CrowdStreet&#8217;s New CEO John Imbriglia Charts a Bold Path for Commercial Real Estate Investors</a>
<h2 class="wp-block-heading">2. Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>): The Monthly Dividend Machine</h2>
Dividend Yield: 5.37% Market Cap: $51.55 billion Sector: Retail
Nicknamed "The Monthly Dividend Company," Realty Income is a household name in income investing. Offering a 5.37% yield, O maintains a strong foothold in retail real estate, with a portfolio diversified across industries and tenants. Despite modest performance year-to-date (1.57%), its P/FCF of 15.84 underscores solid fundamentals.
Realty Income's consistent payouts and reputation for reliable income make it a cornerstone for dividend-focused portfolios. Whether the market&#8217;s hot or cold, this REIT remains a fan favorite for its unwavering commitment to shareholder returns.
<h2 class="wp-block-heading">3. VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>): A Jackpot For Investors</h2>
Dividend Yield: 5.20% Market Cap: $34.60 billion Sector: Diversified
VICI Properties owns an enviable portfolio of casino and gaming assets, including Las Vegas landmarks. Its 5.20% dividend yield is paired with a P/FCF of 15.01, making it the most attractively valued among our picks. Over the past six months, VICI has outperformed with a 16.18% gain, outpacing broader market indices.
As the gaming industry recovers post-pandemic, VICI is well-positioned to capture growth while rewarding investors with consistent income. With its diversified exposure and high yield, this REIT is a safe bet for any portfolio.
These REITs—Healthpeak, Realty Income, and VICI Properties—combine strong dividend yields with promising growth, backed by Wall Street's confidence. 
Whether you're looking for healthcare stability, retail reliability, or a gamble on casinos, these large-cap REITs deliver income with the potential for capital appreciation. For investors, the choice is clear: when it comes to dividends, these are the real estate crown jewels.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/reit/24/11/42044923/goldman-sachs-turns-bearish-on-redfin-affordability-could-weigh-on-a-housing-recovery">Goldman Sachs Turns Bearish On Redfin: &#8216;Affordability Could Weigh On A Housing Recovery&#8217;</a></li>
</ul>

REIT

Dividends

Real Estate

VICI

High-Yield REITs To Watch: Three Wall Street-Approved S&P 500 Gems

Leidos Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) short percent of float has risen 29.05% since its last report. The company recently reported that it has 1.91 million shares sold short, which is 1.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Leidos Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732822222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Leidos Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Leidos Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Leidos Holdings's peer group average for short interest as a percentage of float is 3.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

LDOS

(LDOS) - Analyzing Leidos Holdings's Short Interest

Roku's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NYSE">ROKU</a>) short percent of float has risen 40.13% since its last report. The company recently reported that it has 12.52 million shares sold short, which is 11.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Roku Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732822217_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Roku has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Roku's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Roku's peer group average for short interest as a percentage of float is 8.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ROKU

Peering Into Roku's Recent Short Interest

Israel's ceasefire agreement with Hezbollah which entered into force on Wednesday appears to be unraveling after alleged violations by the Lebanese militant group prompted <a href="https://www.benzinga.com/topic/israel">an Israeli military response</a>.
According to the Israel Defense Forces (IDF), a Hezbollah-linked facility in southern Lebanon was targeted in an airstrike on Thursday after suspicious activity was identified. 
The site reportedly housed medium-range rockets, which were deemed a potential threat.
<h3 class="wp-block-heading">IDF&#8217;s Response To Alleged Breaches</h3>
IDF spokesperson Avichay Adraee announced on X that several suspects, some traveling in vehicles, were spotted entering multiple areas in southern Lebanon, violating the ceasefire agreement. IDF forces responded by opening fire on the group.
Adraee further stated that &#8220;terrorist activity was detected at a Hezbollah site in southern Lebanon, which contained medium-range rockets.&#8221; He confirmed that Israeli warplanes carried out a strike to neutralize the threat.
&#8220;The IDF is deployed in southern Lebanon and is actively working to prevent any violations of the ceasefire agreement,&#8221; Adraee added.
He also issued a warning to residents of southern Lebanon, emphasizing that movement south of the Litani River is strictly prohibited between 5 p.m. and 7 a.m. local time.
Separately, Avital Leibovich, director of the American Jewish Committee Israel Office, highlighted that Hezbollah operatives had entered the village of Kfarkela near the Israeli border, where they are prohibited under the agreement. In response, IDF forces fired warning shots toward the group.
<h3 class="wp-block-heading">Markets React To Renewed Middle East Tensions</h3>
Commodities showed reactions following the latest headlines in Middle East. 
Oil futures rose 0.5% on Thursday, with West Texas Intermediate (WTI) prices – tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) – climbing to $68.9 a barrel, marking a potential end to a three-day losing streak. 
Gold futures edged up 0.4%, continuing a strong rally. The precious metal is now eyeing its sixth consecutive positive session as investors turn to safe-haven assets amid geopolitical uncertainty.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42225506/canada-prepares-retaliatory-tariffs-as-trumps-threat-looms-analysts-warn-of-further-loonie-weakness">Canada Prepares Retaliatory Tariffs After Trump Threats: Analysts Warn Of Further Loonie Weakness</a></li>
</ul>
Image: Shutterstock

Commodities

Politics

Global

Econ #s

Israel-Hezbollah Ceasefire Violations Spark Tensions, IDF Strikes Southern Lebanon: Oil Prices Surge

Recursion Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NYSE">RXRX</a>) short percent of float has fallen 26.22% since its last report. The company recently reported that it has 64.57 million shares sold short, which is 18.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Recursion Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732822212_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Recursion Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Recursion Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Recursion Pharmaceuticals's peer group average for short interest as a percentage of float is 10.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RXRX

(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest

Mobileye Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NYSE">MBLY</a>) short percent of float has risen 5.96% since its last report. The company recently reported that it has 21.69 million shares sold short, which is 30.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mobileye Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732821320_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mobileye Global has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mobileye Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mobileye Global's peer group average for short interest as a percentage of float is 5.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MBLY

Looking Into Mobileye Global's Recent Short Interest

Lucid Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NYSE">LCID</a>) short percent of float has risen 8.05% since its last report. The company recently reported that it has 293.56 million shares sold short, which is 18.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lucid Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732821315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lucid Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lucid Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lucid Gr's peer group average for short interest as a percentage of float is 7.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LCID

How Is The Market Feeling About Lucid Gr?

GameStop's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) short percent of float has fallen 11.3% since its last report. The company recently reported that it has 31.87 million shares sold short, which is 8.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GameStop Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732821310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GameStop has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GameStop's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GameStop's peer group average for short interest as a percentage of float is 3.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into GameStop's Recent Short Interest

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is <a href="https://www.benzinga.com/quote/TSLA/news">turning heads again</a>, this time with a quirky and futuristic touch: a Cybertruck horn update, rolled out through its mobile app. 
Yes, you read that right—Tesla is flexing its software chops by letting Cybertruck owners <a href="https://x.com/cybertruck/status/1861927109746372644">swap their horn</a> sound for something distinctly cyberpunk.
<h2 class="wp-block-heading">Tesla's Cybertruck Horn Update: A Soundtrack For The Future</h2>
Social media lit up as owners shared their delight with the new tone, <a href="https://www.teslarati.com/tesla-cybertruck-horn-update-mobile-phone-app/">described</a> as a blend of Transformers-like sound effects and a touch of sci-fi swagger. The updated horn not only matches the Cybertruck's brutalist, angular aesthetic but feels straight out of a dystopian blockbuster. 
And here's the kicker: the upgrade is free, permanent, and unapologetically cool.
Tesla's message to users cheekily pitched the change as perfect for anyone tired of "traditional" horns or feeling a twinge of FOMO over Cybertruck's futuristic edge. 
While traditional carmakers wrestle over hybrid engines, Tesla is perfecting the art of horn envy.
Read Also: <a href="https://www.benzinga.com/24/11/42231528/tesla-offers-lease-buyout-option-for-all-models-despite-elon-musks-robotaxi-ambitions-could-autonomous-driving-be-further-away">Tesla Offers Lease Buyout Option For All Models, Including Cybertruck, Despite Elon Musk&#8217;s Robotaxi Ambitions: Is Autonomous Driving Further Away?</a>
<h2 class="wp-block-heading">Self-Driving Taxis: Tesla Gets Real</h2>
Meanwhile, in the world of Tesla's autonomous dreams, a recent job <a href="https://www.iotworldtoday.com/transportation-logistics/tesla-seeks-teleoperators-to-remotely-drive-cars#close-modal">posting</a> reveals the company's not-so-quiet pivot: teleoperation. Tesla is hiring engineers to help human operators remotely control its self-driving cars. Think VR rigs, low-latency streaming, and humans stepping in when AI faces a curveball.
Why the shift? Tesla's grand promise of AI-driven, fully autonomous cars—boldly dubbed "Level 5 autonomy"—has hit a wall. 
While competitors like Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo and General Motors Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) Cruise rely on lidar and geofenced areas for their robo-taxis, Tesla's pure vision-based approach hasn't reached the finish line.
The teleoperation team hints at a pragmatic twist to Elon Musk's lofty ambitions. With Cybercabs and robotic fleets teased at <a href="https://www.benzinga.com/news/24/10/41350962/tesla-key-exec-says-we-robot-event-had-1-300-perfectly-safe-autonomous-trips-driving-over-2-000-gues">Tesla's "We, Robot" event</a>, human assistance could bridge the gap between today's reality and Musk's sci-fi future.
<h2 class="wp-block-heading">What's Next For Tesla?</h2>
Tesla's dual strategy of showmanship and engineering is alive and well. From turning a horn update into a viral sensation to quietly building a human safety net for self-driving dreams, the company continues to innovate in its signature, headline-grabbing style. 
For investors, it's a reminder: with Tesla, the future always comes with a twist—and often, a new sound.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42230493/nvidias-next-big-catalyst-analyst-sees-jensen-huang-led-companys-stock-jumping-27-by-early-2025">Nvidia&#8217;s Next Big Catalyst? Analyst Sees Jensen Huang-Led Company&#8217;s Stock Jumping 27% By Early 2025</a></li>
</ul>

Tech

GOOG

GOOGL

TSLA

Tesla's Cybertruck Horn Is Transforming, So Is Its Self-Driving Strategy

In the current session, the stock is trading at $281.96, after a 0.63% spike. Over the past month, Tractor Supply Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) stock increased by 6.20%, and in the past year, by 34.22%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732820414_0.png" alt="Past Year Chart" />

<h3>Tractor Supply P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Tractor Supply has a better P/E ratio of 27.26 than the aggregate P/E ratio of 18.22 of the Specialty Retail industry. Ideally, one might believe that Tractor Supply Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732820414_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

TSCO

A Look Into Tractor Supply Inc's Price Over Earnings

Sherwin-Williams's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) short percent of float has risen 110.69% since its last report. The company recently reported that it has 6.41 million shares sold short, which is 2.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sherwin-Williams Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732819520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sherwin-Williams has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sherwin-Williams's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sherwin-Williams's peer group average for short interest as a percentage of float is 3.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SHW) - Analyzing Sherwin-Williams's Short Interest

Cerence's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NYSE">CRNC</a>) short percent of float has fallen 3.97% since its last report. The company recently reported that it has 6.52 million shares sold short, which is 21.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cerence Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732819514_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cerence has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cerence's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cerence's peer group average for short interest as a percentage of float is 3.59%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRNC

How Is The Market Feeling About Cerence?

AvalonBay Communities's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) short percent of float has fallen 4.84% since its last report. The company recently reported that it has 2.82 million shares sold short, which is 2.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AvalonBay Communities Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732819509_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AvalonBay Communities has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AvalonBay Communities's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AvalonBay Communities's peer group average for short interest as a percentage of float is 4.19%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About AvalonBay Communities?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Every investment category must answer the big question, why? For undervalued <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>, it comes down to advantaging a supremely relevant sector without paying full price.



Of course, the broader healthcare ecosystem offers a compelling narrative for market participants. As the Covid-19 pandemic demonstrated, no matter how advanced we become as a society, a microscopic virus can impose devastation. In order to protect individuals and communities at large, enterprises need a way to address diseases: infectious, chronic, whatever the case may be.



Further, undervalued biotech stocks enjoy a massive canvas for value expansion. According to Grand View Research, the global biotech arena <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">could be worth $3.88 trillion by 2030</a>. If so, that would imply a compound annual growth rate (CAGR) of 13.96% from 2023.



Plus, let&rsquo;s consider the unfortunate rise of cancer and other serious diseases. It wouldn&rsquo;t be surprising in the least if the aforementioned projection was conservative. With that in mind, below are undervalued biotech stocks to consider.



<h2>Procaps (PROC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png" alt="Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock"><div>Source: Hernan E. Schmidt / Shutterstock.com</div></div>Based in Luxembourg, Procaps (NASDAQ:<a href="https://investorplace.com/stock-quotes/proc-stock-quote/">PROC</a>) develops, produces and markets pharmaceutical solutions. It formulates and manufactures <a href="https://finance.yahoo.com/quote/PROC/profile/">branded prescription drugs</a> in multiple therapeutic areas, such as feminine care, pain relief, skin care and digestive health, among other needs. It should be noted that since the start of the year, PROC lost more than 41% of its equity value. Still, for those who want to speculate on undervalued biotech stocks, PROC could be a high-risk, high-reward idea. Right now, shares trade hands at 0.65X trailing-year sales. For the drug manufacturing sector, the median <a href="https://www.gurufocus.com/stock/PROC/summary?search=proc">value stands at 2.08X</a>. More importantly, the market has already demonstrated that it will accept a higher valuation for the business.



Over the last four quarters, PROC stock traded at an <a href="https://finance.yahoo.com/quote/PROC/key-statistics/">average sales multiple of around 0.94X</a>. Theoretically, then, the biotech room can potentially grow into its prior valuation. Over the longer term, that&rsquo;s what Wall Street experts are anticipating.



For fiscal 2024, sales could rise 3.5% to reach $424.15 million. In the following year, the top line could bump up to $460.35 million.



<h2>MiMedx (MDXG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>Headquartered in Marietta, Georgia, MiMedx (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdxg-stock-quote/">MDXG</a>) develops and <a href="https://finance.yahoo.com/quote/MDXG/profile/">distributes placental tissue allografts</a> for various sectors of the healthcare ecosystem. Specifically, MiMedx processes human placental tissues through its proprietary process to produce allografts. This methodology carries the advantage of retaining the tissue&rsquo;s inherent biological properties and regulatory proteins.



MDXG stock is a speculative entity, losing about 12% of market value since the start of the year. Nevertheless, the red ink may be creating a discounted opportunity. Presently, MDXG trades at 3.21X trailing-year revenue. However, during the first quarter of this year, the multiple did pop up to 3.5X. On the surface, that might not seem like much of a discount.



Still, it&rsquo;s important to consider what experts are anticipating moving forward. For fiscal 2024, they&rsquo;re targeting revenue of $361.49 million. If so, that would represent a 12.4% lift from last year&rsquo;s print of $321.48 million. And fiscal 2025 could see the top line move up to $406.17 million, another 12.4% leap.



To be sure, MiMedx represents a higher-risk idea. Still, it qualifies as one of the undervalued biotech stocks to consider.



<h2>MEI Pharma (MEIP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>Operating out of San Diego, California, MEI Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/meip-stock-quote/">MEIP</a>) is a small outfit, featuring only 46 full-time employees. It&rsquo;s a clinical-stage pharmaceutical firm, focusing on the development and commercialization of various therapies for the treatment of cancer. The company has developed a <a href="https://finance.yahoo.com/quote/MEIP/profile/">therapeutic called Zandelisib</a>, which addresses relapsed and refractory follicular lymphoma.



Another high-risk entity, MEIP stock dropped almost 52% of equity value since the start of the year. However, it also appears that the volatility has slowed down. In the trailing month, shares only slipped about 0.3%. Further, the sales multiple seems attractive at only 0.29X. In the past year (Q1 2023 to Q1 2024), the multiple averaged about 0.59X.



It&rsquo;s also worth pointing out that MEIP trades at a trailing-year earnings multiple of 0.74X. Moving forward to the end of the year, analysts anticipate earnings per share to reach $3.62. On the top line, sales may enjoy a 33.8% lift to $65.3 million. Assuming these projections hold true, MEIP could easily grow into its valuation on earnings and sales. Thus, it&rsquo;s one of the undervalued biotech stocks to consider.



<h2>Incyte (INCY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/incy-stock-1-300x169.jpg" alt="incy stock"><div>Source: Eyesonmilan / Shutterstock.com</div></div>Based in Wilmington, Delaware, Incyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/incy-stock-quote/">INCY</a>) is a biopharmaceutical firm engaged in the discovery, development and commercialization of therapeutics for hematology and oncology. It also specializes in conditions revolving around inflammation and autoimmunity. It&rsquo;s a sizable player compared to the speculative plays among undervalued biotech stocks, with more than 2,500 full-time employees.



Financially, Incyte is a solid entity. During the trailing 12 months (TTM), Incyte posted net income of $745.44 million or earnings of $3.30 per share. Revenue reached $3.77 billion. Still, INCY stock trades at 3.64X trailing-year sales. Over the past year, this stat averaged 3.98X.



On the bottom line, the market prices INCY at 13.16X forward earnings. In the past year, the average multiple clocked in at 14.61X. But here&rsquo;s the kicker: analysts anticipate sizable expansion of the top and bottom lines.



Fiscal 2024 could see EPS at $4.30, up 22.16% over the prior year. Revenue could jump 10.6% to reach $4.09 billion. Therefore, it&rsquo;s one of the undervalued biotech stocks to put on your radar.



<h2>United Therapeutics (UTHR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/uthr_unitedtheraputics1600-300x169.png" alt="In this photo illustration United Therapeutics Corporation (UTHR) logo is seen on a mobile phone screen."><div>Source: viewimage / Shutterstock.com</div></div>Headquartered in Silver Spring, Maryland, United Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/uthr-stock-quote/">UTHR</a>) engages in the development and commercialization of products to address unmet medical needs, particularly for patients suffering from chronic and life-threatening diseases. It offers multiple products, including <a href="https://finance.yahoo.com/quote/UTHR/profile/">Tyvaso DPI</a>, which is an inhaled dry powder for the treatment of pulmonary arterial hypertension (PAH).



Financially, United represents another solid idea among undervalued biotech stocks. Net income during the TTM period landed at $1.05 billion or $21.13 per share. Revenue in the cycle reached $2.5 billion. Currently, the market prices UTHR stock at 6.34X trailing-year sales, which admittedly is at a premium.



However, analysts believe that in fiscal 2024, sales could hit $2.74 billion, up 17.8% from the prior year&rsquo;s tally of $2.33 billion. Assuming a shares outstanding count of $44.37 million, UTHR would trade at a projected sales multiple of around 5.16X.



Now, the average multiple over the past year came in at 5.24X. So, ever so slightly, UTHR ranks among the undervalued biotech stocks. Plus, the benefit here is that you&rsquo;re dealing with a profitable and growing enterprise.



<h2>Harmony Biosciences (HRMY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Operating out of Plymouth Meeting, Pennsylvania, Harmony Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrmy-stock-quote/">HRMY</a>) is a commercial-stage pharmaceutical firm focusing on the development and commercialization of therapies for patients with rare and neurological diseases. Its <a href="https://finance.yahoo.com/quote/HRMY/profile/">main product is WAKIX</a>, a molecule with a novel mechanism for the treatment of excessive daytime sleepiness in adults with narcolepsy.



For a relatively small enterprise, Harmony offers robust financials. During the TTM period, the company posted net income of $137.7 million or earnings of $2.32 per share. On the top line, sales in the period reached $617.51 million. In the most recent quarter, HRMY&rsquo;s quarterly sales growth rate (year-over-year0 landed at 29.8%.



Right now, HRMY stock trades at 2.91X trailing-year sales. In the past one-year period, the average multiple stood at 4.05X. Even better, covering experts see Harmony&rsquo;s revenue rising by 22% to $710.15 million. Further, the high-side target runs up to $718.4 million.



For fiscal 2025, the consensus view calls for $836.82 million, up 17.8%. As a bonus, EPS in fiscal 2025 may also soar nearly 75% to $3.90. It&rsquo;s one of the undervalued biotech stocks to consider.



<h2>ScyNexis (SCYX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Based in Jersey City, New Jersey, ScyNexis (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) falls under the drug manufacturing ecosystem. <a href="https://finance.yahoo.com/quote/SCYX/profile/">Per its public profile</a>, ScyNexis develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections. One of its main products is Brexafemme for the treatment of patients with certain feminine conditions. It also offers other treatments for important but sensitive conditions.



SCYX stock is a difficult entity to bet on. Since the start of the year, it lost about 10% of market value. Over the past 52 weeks, it&rsquo;s down about 34%. At the same time, it also offers some financial substance. During the TTM period, the company posted net income of $101.33 million or $2.11 per share. Revenue landed at $140.38 million. Its latest quarterly sales growth rate clocked in at 21.5%.



That said, analysts anticipate an 82% erosion in the top line for fiscal 2024 to $25.1 million. Last year, the company generated sales of $140.14 million. Obviously, that&rsquo;s not a great look, leading to a trailing-year sales multiple of 0.69X. In the past year, this stat averaged 10.41X.



However, in fiscal 2025, a gradual recovery trek may materialize, resulting in sales of $44.07 million. Further, the high-side target calls for $116.25 million, making SCYX potentially one of the undervalued biotech stocks.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/7-undervalued-biotech-stocks-to-buy-for-big-time-returns/">7 Undervalued Biotech Stocks to Buy for Big-Time Returns</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Procaps Group (PROC) has released an update. Procaps Group is undergoing an internal investigation regarding historical accounting treatments and f...

Procaps Group Faces Audit Report Withdrawal Amid Investigation

Procaps Group (PROC) has released an update. Procaps Group, S.A. has entered into forbearance agreements with its creditors concerning approximatel...

Procaps Group Negotiates Forbearance on Debt

Procaps Group (PROC) has released an update. Procaps Group CEO José Antonio Vieira has reiterated his commitment to guiding the company to growth, ...

Procaps Group Navigates Challenges, Outperforms Market

Procaps Group (PROC) has released an update. Procaps Group has announced a significant milestone in its financial restructuring, having secured for...

Procaps Group Advances Strategic Financial Restructuring

Procaps Group (PROC) has released an update. Procaps Group, S.A. has announced the immediate resignation of Mr. Ruben Minski from its Board of Dire...

Procaps Group Announces Board Resignation

Procaps Group (PROC) has released an update. Procaps Group, S.A. has announced its intention to restate financial statements due to errors and miss...

Procaps Group Announces Financial Restatement Plans

Procaps Group (PROC) has released an update. Procaps Group is taking strategic steps to navigate financial challenges, including appointing a new b...

Procaps Group's Strategic Moves for Financial Stability

Procaps Group (PROC) has released an update. Procaps Group faces potential suspension and delisting from Nasdaq due to delays in filing its 2023 fi...

Procaps Group Seeks Nasdaq Resolution Amid Filing Delays

Procaps Group (PROC) announced that, on November 13, the company received formal notice from the Listing Qualifications Department of The Nasdaq St...

Comments

Procaps Gr

ニュース

最新ニュース Procaps Gr (NASDAQ:PROC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル